Bone marrow stromal cell transplants prevent experimental enterocolitis and require host CD11b+ splenocytes

Area of Science:

• Immunology
• Cell Therapy
• Gastroenterology

Background:

• Mesenchymal stem cells (MSCs) show promise for treating immune-mediated diseases.
• Investigating MSC efficacy in chemically induced colitis models is crucial.
• Understanding the role of CD11b(+) cells in MSC therapy is key.

Purpose of the Study:

• To evaluate the therapeutic effects of MSCs in a mouse model of colitis.
• To determine the role of CD11b(+) cells in MSC-mediated immune modulation.
• To test the hypothesis that MSCs enhance regulatory T cell populations.

Main Methods:

• Colitis was induced using trinitrobenzene sulfonic acid in mice.
• MSC treatment efficacy and survival rates were monitored.
• Regulatory T cell numbers and CD11b(+) cell interactions were assessed in vitro and in vivo.

Main Results:

• MSC treatment prevented colitis and improved survival.
• MSCs increased regulatory T cell numbers in mesenteric lymph nodes.
• The therapeutic effect of MSCs was dependent on CD11b(+) cells.

Conclusions:

• MSC transplantation is a viable treatment for colitis in mice.
• The interaction between MSCs and CD11b(+) regulatory T cells is critical for therapeutic efficacy.
• This interaction may inform the development of MSC potency assays and novel cell therapies.